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Abstract
Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clini-
cal criteria. Disease activity and burden are best measured with a composite score, assessing both objective and subjec-
tive symptoms, such as SCORing Atopic Dermatitis (SCORAD). AD management must take into account clinical and
pathogenic variabilities, the patient’s age and also target flare prevention. Basic therapy includes hydrating and barrier-
stabilizing topical treatment universally applied, as well as avoiding specific and unspecific provocation factors. Visible
skin lesions are treated with anti-inflammatory topical agents such as corticosteroids and calcineurin inhibitors (tacroli-
mus and pimecrolimus), which are preferred in sensitive locations. Topical tacrolimus and some mid-potency corticos-
teroids are proven agents for proactive therapy, which is defined as the long-term intermittent anti-inflammatory therapy
of frequently relapsing skin areas. Systemic anti-inflammatory or immunosuppressive treatment is a rapidly changing
†See Appendix section.
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field requiring monitoring. Oral corticosteroids have a largely unfavourable benefit–risk ratio. The IL-4R-blocker dupilu-
mab is a safe, effective and licensed, but expensive, treatment option with potential ocular side-effects. Other biologicals
targeting key pathways in the atopic immune response, as well as different Janus kinase inhibitors, are among emerging
treatment options. Dysbalanced microbial colonization and infection may induce disease exacerbation and can justify
additional antimicrobial treatment. Systemic antihistamines (H1R-blockers) only have limited effects on AD-related itch
and eczema lesions. Adjuvant therapy includes UV irradiation, preferably narrowband UVB or UVA1. Coal tar may be
useful for atopic hand and foot eczema. Dietary recommendations should be patient-specific, and elimination diets
should only be advised in case of proven food allergy. Allergen-specific immunotherapy to aeroallergens may be useful
in selected cases. Psychosomatic counselling is recommended to address stress-induced exacerbations. Efficacy-pro-
ven ’Eczema school’ educational programmes and therapeutic patient education are recommended for both children
and adults.
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This article is the 4th edition of the European Task Force on
Atopic Dermatitis (ETFAD) of the European Academy of Der-
matology and Venerology (EADV) position paper. Like the ear-
lier versions,1–3 it communicates the experience, opinion and
recommendation of the ETFAD on the current treatment and
management options for atopic dermatitis (AD) in view of
recently updated relevant guidelines,4,5 position papers6 and rel-
evant original data from the point of view of care-giving expert
physicians regularly involved in managing patients with AD. It is
by intention neither a guideline, nor a systematic review, but a
short expert opinion paper communicating clinically useful
information for diagnosing and treating AD.
Introduction and definitions
Atopic dermatitis (syn. atopic eczema, eczema, neurodermitis) is
an inflammatory, chronically relapsing and intensely pruritic
skin disease often occurring in families with atopic diseases (AD,
food allergy, bronchial asthma or allergic rhinoconjunctivitis).
The current understanding indicates that AD is a systemic T-
helper (Th) 2-driven disease, in which the prevalence of atopic
comorbidities is high, in particular in patients with moderate-
to-severe AD.7 From a clinical and histopathological standpoint,
AD is an eosinophilic/spongiotic inflammation of the skin with
characteristic age-dependent distribution patterns and morphol-
ogy of lesions. With a prevalence of 2%–10%8 in young adults
and up to 20% in children, AD is one of the most common skin
diseases. The varying aetiologic concepts of this disease are mir-
rored by the different names that are or have been used, such as
‘neurodermatitis’, ‘neurodermitis’ and ’endogenous/constitu-
tional eczema’.
Atopy can be defined as familial hypersensitivity of the skin
and the mucosa to environmental substances, associated with
increased production of immunoglobulin E (IgE) or altered
pharmacologic reactivity.9 The ETFAD defines atopy as the ’fa-
milial tendency to develop Th2 responses against common envi-
ronmental antigens’, which keeps both IgE-associated, extrinsic
and non-IgE-associated, intrinsic subtypes10 within the defini-
tion of atopy.
The atopic diseases are genetically linked, and the concor-
dance in monozygotic twins is 80% vs. 30% in dizygotic twins.11
Described genetic polymorphisms in AD involve mediators of
atopic inflammation on different chromosomes, and some of
these are also relevant for respiratory atopy. The strongest
association has been shown with mutations in the filaggrin gene
also associated with ichthyosis vulgaris, highlighting the predis-
posing barrier defect in AD patients.12 Concomitant ichthyosis
vulgaris can be diagnosed clinically, and increased palmar hyper-
linearity is a good indicator of filaggrin gene mutations.13 In the
first months of life, a yellowish layer of seborrhoeic, crusted
scales on the scalp, known as ‘cradle cap’, may be the first pre-
sentation of AD and can be treated with emollients only. AD
usually starts in the face, with middle face sparing, and on the
extensor surfaces of the arms and legs of toddlers, as well as the
trunk, sometimes showing extensive oozing and crusting. Later
on, eczematous involvement of flexures, neck and hands pre-
dominates, accompanied by dry skin. The skin barrier dysfunc-
tion is reflected by an increased transepidermal water loss
(TEWL).14 Measuring TEWL with an evaporimeter and dis-
cussing the results with the patient will increase adherence to
recommended emollient therapy. Lichenification is the result of
scratching and rubbing, frequently at night-time. The prurigo
type of AD is associated with predominant excoriated, nodular
and lichenified lesions. Exacerbations often start as increased
itch without visible skin lesions, followed by erythema, papules
and infiltration. As histopathologic features are not specific for
AD, routine histology is not useful for diagnosing AD, but may
help to rule out differential diagnoses, such as cutaneous T-cell
lymphoma in adults.3
In the absence of a specific diagnostic laboratory marker, AD
is diagnosed clinically. The diagnostic power of an experienced
clinician is superior to all diagnostic criteria available, but stan-
dardized criteria are needed for epidemiological research, as well
as for inclusion criteria for clinical trials. Most diagnostic criteria
are based on cutaneous signs of atopy.9,15 Hanifin and Rajka’s
criteria include pruritus, typical morphology and distribution,
chronic or chronically relapsing course, and atopic personal or
family history (3 of 4 necessary), in addition to 3 minor criteria
among a list of 21.15 According to the UK working party criteria,
itchy skin changes have to be diagnosed in the last 12 months,
in addition to at least three of the following criteria: onset of the
disease under the age of two years, history of involvement of skin
folds, generalized dry skin, other atopic diseases and visible flex-
ural eczema.16
Atopic dermatitis has a profound impact on all dimensions of
the patient’s life.17,18 Moderate-to-severe AD is associated with
depression, anxiety, reduced quality of life, impaired self-esteem
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and suicide.19 The social impact of moderate-to-severe AD is
high and similar to the one of psoriasis, chronic obstructive
bronchitis, cardiovascular disease and diabetes.20
Management of acute exacerbations (flares) of AD is a
therapeutic challenge, as it requires efficient short-term con-
trol of acute symptoms, without compromising the overall
management plan that targets long-term stabilization, flare
prevention and avoidance of side-effects. Exacerbation may
sometimes uncover relevant provocation factors, such as
underlying allergies or infection. Consequently, the initial
workup must include a detailed inquiry on the circumstances
of the flare, and a careful dermatologic examination including
lymph nodes, orifices and all skin folds. Professional attitude
in face of exacerbated disease is setting the stage for future
adherence.21 Patients often have their own beliefs about the
origin of their flare, but disparaging remarks at this time will
only increase patient or parental frustration with conventional
medicine. Patient fears regarding treatment side-effects must
be taken seriously with a compassionate attitude. Therapeutic
patient education is an extremely helpful tool to address
patient beliefs and questions regarding disease and treat-
ment.22
Assessment of disease activity
As atopic dermatitis is a chronic disease, long-term management
strategies are essential to consider. Consensus definitions for
management procedures are necessary.23 In clinical trials, three
methods have been used to assess long-term control: repeated
measurement of AD outcomes, amount of medication used and
recording of AD flares/remissions.24
The notion of intolerance or resistance to topical treat-
ments is a clinically meaningful soft term for inadequate AD
improvement using potent topical corticosteroids (TCS) with
intolerable long-term side-effects. As quantitative rules for
prescription of topicals are rarely applied, it is difficult to
refer to an upper limit to define resistance.3 Very often,
patients apply too little amounts of TCS leading to the per-
ception of a lack of effect.
Overall disease activity should assess both objective and sub-
jective symptoms, as both contribute to clinical severity.3 This
can be achieved with the SCORAD index.25 Mild AD corre-
sponds to SCORAD levels below 25 and severe AD to SCORAD
levels above 50.26
Flare is a clinically meaningful term difficult to delineate.27
Repeated measurements and arbitrary cut-offs of an existing
severity scale, such as SCORAD,25 measured at sequential
intervals by physicians, have been used most frequently in
the past.27 However, defining flares based on the intensity of
itch is difficult, as the level of tolerance to pruritus can vary
largely.3 Some patients with highly lichenified lesions report
only moderate pruritus and insomnia. The amount of medi-
cation used by the patient can be measured to detect
variations or flares. Novel tools for patient use like the
patient-oriented (PO) validated scoring system PO-SCORAD
may detect changes in signs and symptoms.28 A valid, reliable
and feasible flare definition acceptable for all clinical and
research settings has still not been consented.27 The ETFAD
definition of flare is ’acute, clinically significant worsening of
signs and symptoms of AD requiring therapeutic interven-
tion’ (see Table 1 for ETFAD definitions). Primary clinical
outcome measures used in recent development programmes
include the achievement of clear or almost clear skin (investi-
gator global assessment of 0 or 1) or a 75% improvement in
severity scores such as ’Eczema Area and Severity Index’
(EASI) or SCORAD.29 In addition, clinically relevant
improvement in itch, as defined by a 3- to 4-point improve-
ment in the 10-point itch numerical rating scale, is desirable.
Maintaining a long-term remission is a shared objective in
chronic disorders. A widely accepted and uniform nomenclature
would help to compare data. Long-term remission without
lesions and treatment is usually synonym of cure, but the time
without intervention that may correspond to such a situation is
still to be defined. Remission achieved by the avoidance of irri-
tants and allergens with sole emollient use is not comparable to
remission under immunosuppressive agents or biologics
(Table 1). Other proposals come from asthma management
(weeks with complete control/ weeks with good control) or from
pragmatically oriented judgement (increase in treatment, medi-
cal visit or call).30 Kaplan–Meier diagrams comparing flare-free
percentages of study populations using study drug and control
for 1 year (or at least 3 months) is a clinically meaningful visual-
ization for flare prevention studies.3 Data extraction of ’percent
patients flared at study end’ from treated patients may produce
misleading meta-analysis results,31 whereas prolongation of time
to first flare in 50% of treated vs untreated patients, or compar-
ing the percentage of flare-free patients at a fixed time (e.g.
12 weeks), is recommended.32 Long-term control scores for use
in clinical trials have recently been developed by international
teams.33
Basic therapy for atopic dermatitis and skincare
Since AD is a chronic condition, treatment has to be planned
with a long-term perspective and special attention must be given
to long-term safety aspects.
Cleansing
The skin must be cleansed thoroughly, but gently and carefully
to get rid of crusts and mechanically eliminate bacterial contam-
inants, especially in the case of bacterial superinfection. Cleans-
ers with or without antiseptics in non-irritant and low allergenic
formulas may be used in various galenic forms such as syndets
or aqueous solutions. As the duration of action of some antisep-
tics is very limited, mechanical cleansing is probably more
important.34 The pH should be in a physiological cutaneous
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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range around 5–6, but if possible, lower pH products are gener-
ally good for the skin barrier. A small randomized study did not
show any difference in bathing twice weekly or everyday with
respect to AD severity,35 as long as hydration of skin is managed
after the bath. However, longer duration of the bath is associated
with worsening of the symptoms.36
Treatment of atopic dermatitis: adult
•  For every grade, additional therapeutic options are given
•  Add antiseptics / antibiotics in cases of superinfection
•  Consider compliance and diagnosis, if therapy has no effect
•  Refer to full text for restrictions, especially for treatment marked with 1
•  Licensed indication are marked with 2, off-label treatment options are marked with 3
Treatment of atopic dermatitis: children
•  For every grade, additional therapeutic options are given
•  Add antiseptics / antibiotics in cases of superinfection
•  Consider compliance and diagnosis, if therapy has no effect
•  Refer to full text for restrictions, especially for treatment marked with 1
•  Licensed indication are marked with 2, off-label treatment options are marked with 3
SEVERE: 
SCORAD >50 / or 
persistent eczema
Hospitalization; 
short course of cyclosporin A1,2, dupilumab 2, 
short course of oral glucocorticosteroids 1,2; 
longer course of systemic immunosuppression: methotrexate 3, 
azathioprin 3, mycophenolate mofetil 3;  PUVA 1;  alitretinoin 1,3
SEVERE: 
SCORAD >50 / or 
persistent eczema
Hospitalization; 
dupilumab 1,2;
course of systemic immunosuppression: cyclosporin A 3, 
methotrexate 3, azathioprin 3, 
mycophenolate mofetil 1,3
MODERATE: 
SCORAD 25-50 / or
recurrent eczema
Proactive therapy with topical  tacrolimus 2 or class II or class III 
topical glucocorticosteroids 3, wet wrap therapy, UV therapy (UVB 
311 nm, medium dose UVA1), 
psychosomatic counseling, 
climate therapy
MODERATE: 
SCORAD 25-50 / or
recurrent eczema
Proactive therapy with topical  tacrolimus 2 or class II or class III 
topical glucocorticosteroids 3, wet wrap therapy, 
UV therapy 1 (UVB 311 nm), 
psychosomatic counseling, 
climate therapy
MILD: 
SCORAD <25 / or 
transient eczema
Reactive therapy with topical glucocorticosteroids class II 2 or 
depending on local cofactors:
topical calcineurin inhibitors 2, antiseptics incl. silver 2, 
silver coated textiles 1 
topical crisaborole 3
MILD: 
SCORAD <25 / or 
transient eczema
Reactive therapy with topical glucocorticosteroids class II 2 or 
depending on local cofactors:
topical calcineurin inhibitors 2, antiseptics incl. silver 2, 
silver coated textiles 1 
topical crisaborole 3
BASELINE 
Basic therapy
Educational programmes, 
emollients, bath oils, 
avoidance of clinically relevant allergens 
(encasings, if diagnosed by allergy tests)
BASELINE 
Basic therapy
Educational programmes, 
emollients, bath oils, 
avoidance of clinically relevant allergens 
(encasings, if diagnosed by allergy tests)
(a)
(b)
Figure 1 The treament recommendations according to the ETFAD member consensus for adults (a) and children (b) based on the sever-
ity of the disease
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The most important aspect of washing in AD is the avoidance
of all harsh detergents and alkaline soap. The alternatives include
emollient wash products (bath oils, shower emollient wash prod-
ucts) or using a leave-on emollient cream as a wash product.
Emollient bath additives for the treatment of childhood
eczema showed no clinical benefit if used in addition to using
leave-on emollients as a soap substitute.37 The latter combina-
tion is rarely used in reality. The ideal is to let patients choose
which emollient wash products they prefer, as this will be the
one they will use. Topical emollients are preferentially applied
immediately after a bath or a shower following gentle drying
when the skin is still slightly humid, which is known as ‘soak-
and-seal’ technique.34 Although bathing seems very important,
there is lack of good evidence to prove its effectiveness or specific
parameters of use.
The ETFAD recommends regular bathing or showering in
warm but not hot water about 2–7 times per week with very
mild surfactant and emollient-based wash products in a ‘soak-
and-seal’ approach.
Emollient therapy
Atopic dermatitis is associated with skin barrier anomalies that
facilitate an easier allergen penetration into the skin with an
increased proneness to irritation and subsequent cutaneous
inflammation. A lack of important stratum corneum intercellular
lipids and an inadequate ratio between lipid compounds (choles-
terol, essential fatty acids, ceramides), as well as filaggrin defects,12
enhance TEWL. This leads to epidermal micro-fissuring, which
may also cause direct exposure of Langerhans cell dendrites as well
as nerve endings to the environment. A better molecular and bio-
chemical knowledge on this predisposing background should pro-
vide access to barrier improving topical agents. The use of high-
quality emollients can be cost-effective because they prevent the
development of flares and the need for anti-inflammatory TCS
and TCI.38 Nevertheless, if an acute flare does occur, it is better to
treat with anti-inflammatory topicals first as outlined below,
instead of applying emollients to acute inflamed lesions.39,40
Emollients are not always beneficial, as some can lead to other
skin sensory adverse events such as burning, stinging or pruritus,
especially if the emollients are used on inflamed skin. About 1/3
of adult AD patients have developed contact allergies to ingredi-
ents of their emollients and type IV sensitization to emulsifiers,
preservatives and fragrances being the most common.41 In
patients with this problem, it is best to use the simplest emollient
ointment formulations with the smallest number of ingredients.
By tradition, emollients are defined as topical treatment with
vehicle-type substances lacking active ingredients. Most of them
contain a humectant (promoting stratum corneum hydration,
such as urea or glycerol) and an occludent (reducing evapora-
tion, such as petrolatum).4 Urea is known to significantly reduce
the risk of AD relapse.38
Several non-medicated products for topical treatment of AD
contain putative active ingredients, but are neither fulfilling the
definition of nor needing a licence as a topical drug. These prod-
ucts, referred to as ’emollients plus’ by the European guideline,
may contain, for example, flavonoids such as licochalcone A,
saponins and riboflavins from protein-free oat plantlet extracts,
bacterial lysates from Aquaphilus dolomiae or Vitreoscilla fili-
formis species, or a synthetic derivative of menthol such as men-
thoxypropanediol.4,42 Emollients containing potentially
allergenic plant proteins from peanut, oat or wheat should be
avoided in children before the age of 2,43 whereas protein-free
plant extracts are apparently safe to use.44
The ETFAD recommends the daily use of liberal amounts of
emollients, at least 30 g/day or 1 kg/month for an adult, which
should preferentially be applied in a ‘soak-and-seal’ technique
(Fig. 1).
Table 1 Definitions of descriptive items for the management of
AD
Flare: Acute, clinically significant worsening of signs and symptoms of
atopic dermatitis requiring therapeutic intervention.
Instrument: A unidimensional or multidimensional scoring system used to
measure relevant items of a disease. The EASI, objective SCORAD,
POEM and DLQI are validated instruments for signs, symptoms or quality
of life of AD, whereas the SCORAD is a validated composite score
assessing both signs and symptoms of AD.
Intolerance to topical treatment: Patient’s opinion after at least 2 weeks
of therapy with a new topical treatment, because of worsening of lesions or
any difficulty to apply the drug (ointment not supported, pain, burning or
any uncomfortable sensation).
Items: Measurable disease-related features can be either or both signs
and symptoms.
Proactive therapy: Long-term, low-dose intermittent application of anti-
inflammatory therapy to the previously affected skin, together with an
ongoing emollient treatment of unaffected skin.
Remission/Control: Period without flare of at least 8 weeks without anti-
inflammatory treatment (irritant/allergen avoidance and emollient use not
included).
Complete remission: If using basic treatment (avoidance, emollients)
Incomplete remission: If using moderate treatment, topical
corticosteroids or calcineurin inhibitors less than 30 g/month in children
and less than 60 g/month after 15 years of age
Control: If using major treatment including phototherapy or
immunosuppressants
Severity of disease: The overall impact of signs and symptoms of AD on
a patient, which requires assessment with a composite score.
Mild disease: If SCORAD is <25
Moderate disease: If SCORAD is ≥25 and <50
Severe disease: If SCORAD is ≥50
Sign: A disease-related item captured by an observer. It has the potential
to be objective and reproducible. Signs of AD may be assessed by EASI
and objective SCORAD.
Symptom: A disease-related item captured by a patient. It is by definition
subjective. Most symptoms mirror signs or other symptoms. Symptoms of
AD may be assessed by POEM.
Resistance to topical treatment: Physician’s opinion of a situation with
unchanged or aggravated clinical score after at least 2 weeks of
appropriately dosed and performed treatment.
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Primary prevention
Primary prevention targets the general or an at-risk population
with preventive measures, if there is still no evidence of disease.
Emollients have recently been recommended for primary pre-
vention of AD,45 but there are conflicting data. On one hand, two
pilot randomized trials showed a 32% and 50% relative risk
reduction in incident AD by the daily use of emollients from birth
in neonates who are at high risk of developing AD.46–48 On the
other hand, two recently published larger and longer trials with a
less stringent intervention did not confirm these effects of emol-
lients.49,50 Though emollients are a mainstay of AD treatment, the
role for primary prevention of AD is unclear at present.
Probiotics (inactivated bacteria) and prebiotics (fibres that
can promote the growth of certain bacteria in the gut) have been
studied for primary prevention of AD during pregnancy or in
neonates, but older data were essentially inconclusive. A diagno-
sis of AD is associated with a decreased diversity of neonates’ gut
microbiota.51 A new Cochrane systematic review and meta-anal-
ysis of 21 studies issued the recommendation that a mixture of
probiotic supplementation given to the mother during preg-
nancy and continued, while breastfeeding would be most effica-
cious in reducing the risk of incidence of AD in children.52,53
The ETFAD does not give a recommendation for any dietary
and lifestyle changes aiming at primary prevention of AD,
because the quality of data is not sufficient to issue a sustainable
recommendation for any of the interventions studied.
Avoidance strategies based on a diagnosis of
allergy
Atopic dermatitis is associated in particular with immediate but
also delayed-type hypersensitivity against environmental aller-
gens. Among food allergens, cow’s milk, hen’s egg, wheat, soya,
tree nuts and peanuts are most frequently associated with AD
exacerbation in infants and toddlers. In older children, adoles-
cents and adults, pollen-related food allergies should be taken
into account.54 Irritant factors comprising chemicals and physi-
cal agents may complicate the course of the disease. Finally, con-
tact sensitization to chemicals, drugs, plants or metals is as
frequently found in AD as in non-atopic individuals and may
complicate the clinical severity by overlying allergic contact der-
matitis.55 Diagnosing the individually relevant trigger factors for
AD is more challenging than diagnosing the disease.
The ETFAD recommends an allergy workup for moderate-to-
severe AD patients, which may include serum IgE, skin prick
tests and patch tests for contact sensitization to ingredients of
emollients and topical anti-inflammatory agents, depending on
the individual history. Mild patients may be tested depending on
clinical suspicion.
Food allergens
About one-third of children with a moderate-to-severe AD have
an associated food allergy.56 It is a common misconception that
food allergy would be causative in the setting of AD. Parents
must be warned that general elimination diets are not recom-
mended,57 and can be detrimental.58 In AD children with proven
food allergy, good skincare is also the mainstay of treatment, but
identifying and avoiding trigger factors are important.57
Sensitizations to foods can be identified by means of in vivo
tests (skin prick tests, prick-prick tests) and in vitro tests (serum
specific IgE). A positive test indicates IgE-mediated sensitization,
but may have poor correlation with clinical responses.59 In addi-
tion, atopy patch tests proved to be useful for studying delayed
food-related skin responses.60
A skin prick test (SPT) with food allergens (i.e. cow’s milk,
eggs, wheat, soya, peanut) is suggested in children <5 years with
moderate-to-severe AD that is persistent in spite of optimized
management and topical therapy. Food allergy is less common
in older age groups. Tests are recommended when food allergy is
suspected.
In vitro tests (i.e. specific IgE testing) are valuable when SPT
cannot be applied because of urticaria factitia (urticarial dermo-
graphism), UV- and drug-induced skin hypo-reactivity or lack
of compliance for SPT in infants.61 Moreover, in vitro data of
specific IgE to food allergens allow better quantitative grading of
sensitization, which helps to estimate the probability of the risk
of a clinical reaction and offers the opportunity to test single
recombinant allergens, which may have a better diagnostic speci-
ficity than testing with food extracts. Importantly, skin prick test
reactivity to foods seems to decrease during the first 7 years,
whereas specific IgE against food allergens tend to increase.62
The atopy patch test (APT) for food allergens has been stan-
dardized for selected food and aeroallergens,60,63 but prepara-
tions are expensive, not adequately reimbursed and also not
approved for routine diagnosis by the authorities.60 As a prag-
matic alternative, the APT may be performed with self-made
food material using large test chambers for 48–72 h, but these
test materials are not standardized.64 Whereas immediate-type
reactions are associated with SPT positivity, delayed-type reac-
tions are related to positive responses to APT.65 However, food
challenge cannot be replaced by patch testing.
The best method to prove clinically significant allergy is the
double-blind placebo-controlled food challenge.61 In clinical
reality, elimination and reintroduction of a certain food after a
reliable history can be sufficient. Oral challenging of AD patients
with foods may induce early reactions such as urticaria, gastroin-
testinal or respiratory symptoms usually occurring within 30–
120 min after allergen administration, or eczematous late-phase
responses after 18–48 h. About 45% of oral food challenges
result in both immediate and delayed reactions, whereas 12%
showed worsening of eczema only.66 The personal history has a
low predictive value (30%) for oral challenge-induced late reac-
tions, as opposed to 80% for immediate reactions.66
The ETFAD recommends that an elimination diet for AD
should not be based on type I sensitization detected by blood or
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skin prick tests, but on a reliable history followed by elimination
and reintroduction of suspected food or an oral food challenge if
this is feasible.
Aeroallergens
Clinical observations and experimental studies indicate that
aeroallergens are relevant trigger factors in AD patients.67 Exac-
erbations of eczematous lesions after skin contact or inhalation
have been described, but studies on allergen avoidance strategies
show conflicting results.68 Routine diagnostic workup of sus-
pected allergy to aeroallergens includes detection of specific IgE
by means of skin prick tests or in vitro IgE assays. However, both
techniques have a low predictive value.
Atopy patch test (APT) with aeroallergens targets the cellular
component of AD,63 and has been performed with house dust
mites, pollen and animal dander, obtaining different positivity
rates (15%–100%) according to patch test materials and modali-
ties.60 On the basis of the history of aeroallergen-triggered AD
flares, APTs proved to have higher specificity and lower sensitiv-
ity than the above-mentioned tests63 and may detect sensitiza-
tion in skin prick test negative, ‘intrinsic’ AD patients.65
Unfortunately, standardized aeroallergen preparations are not
available for routine testing in APT so far. As still no feasible
standard procedure for provocation of eczema in aeroallergen-
mediated AD exists, specific avoidance strategies should be con-
sidered for highly sensitized patients with chronic, moderate-to-
severe disease on a patient individual basis (Table 2).
Contact allergy
Contact allergy may be detected in 40%–65% of AD patients
and cause worsening of their skin lesions.69 Factors favouring
allergic contact dermatitis in AD patients include the prolonged
and repeated exposure to ingredients of topical treatments, along
with increased skin barrier penetration.70 Emulsifiers, fragrances,
preservatives, corticosteroids and other components of topical
treatment preparations are the most relevant substances to be
tested.41,69 In addition, contact allergy to compositae plants
should be considered, e.g. when severe facial eczema is observed
during the summer months.71 Children with AD who have long-
lasting moderate-to-severe hand or foot dermatitis should
always be patch-tested to evaluate whether they have an allergic
contact dermatitis.72 Patch testing of AD patients can be tricky,
as Th2 inflammation may suppress contact allergy, which in turn
requires physicians to test when the AD is under control.73 Patch
testing should be considered before systemic intervention is
planned.74 Patch testing of occupational allergens is discussed in
a separate chapter below.
The ETFAD suggests setting a low threshold for performing
patch tests with a standard series and components of topical
treatment preparations in AD patients. In addition, patch testing
is recommended in AD patients with recalcitrant disease,
atypical localization or aggravation without known cause, espe-
cially when systemic intervention is considered.
Topical anti-inflammatory treatment
Effective topical therapy depends on three fundamental princi-
ples: sufficient strength, sufficient dosage and correct applica-
tion.2 Topical treatment should be applied on hydrated skin if
possible, especially when using ointments. If emollients and
anti-inflammatory topical preparations must be applied to the
same location, the cream formulation should be applied first
and only 15 min later the ointment formulation. Even without
wet wraps, topical therapy is time-consuming: patients should
plan 30 min for one session. One well-conducted treatment per
Table 2 List of aggravating factors and counselling for AD
patients
• Clothing: Avoid skin contact with irritating fibres (wool, large fibre textiles).
Do not use tight and too warm clothing to avoid excessive sweating. New
non-irritating clothing, designed for AD children and adults, and especially
silver-coated textiles are encouraged
• Tobacco: avoid exposure
• Cool temperature in bedroom and avoid too many bed covers
• Increase emollient use with cold weather
• Avoid exposure to herpes sores. Urgent visit if flare of unusual aspect
• Vaccines: normal schedule in non-involved skin, including egg-allergic
patients (see text)
• Sun exposure: no specific restriction with careful use. Usually helpful
because of anti-inflammatory effect and improvement of epidermal barrier.
Encourage summer holidays in high altitude or at beach resorts
• Physical exercise, sports: no restriction. If sweating induces flares of AD,
progressive adaptation to exercise. Shower and emollients after swimming
pool
• Food allergens
a Maintain breastfeeding until four months if possible; include all foods
recommended for the given ages after 4 months, unless the child
develops allergy symptoms or sensitization has been shown
b Otherwise normal diet, unless an allergy workup has proven the
need to exclude a specific food
c Some patients show improvement by avoiding foods cross-reactive
to pollen (e.g. birch pollen)
• Indoor aeroallergens
• House dust mites
a Use adequate ventilation of housing. Keep the rooms well-aerated
even in winter
b Avoid wall to wall carpeting
c Remove dust with a wet sponge
d Vacuum with an adequate filtered cleaner once a week floors and
upholstery
e Avoid soft toys in bed (cradle), except washable ones
f Wash bed sheets at a temperature higher than 55° every 10 days
g Bed and pillow encasings in Gore-Tex or similar
• Furred pets: Advice to avoid cats but not dogs preventively. If allergy to
furred pets is demonstrated, be firm on avoidance measures
• Pollen: In sensitized individuals, close windows during peak pollen season
on warm and dry weather and restrict if possible stays outdoors. Aeration
at night and early in the morning or by rainy weather. Avoid exposure to
risk situations (lawn mowing). Pollen filters in car. Clothes and pets can
vectorize aeroallergens, including pollen.
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day is usually sufficient; oozing AD may require a few days with
higher treatment frequency.16
Wet-wrap treatment
Children and adults with acute, oozing and erosive lesions some-
times do not tolerate standard topical application and should be
treated with ’wet wraps’ first until oozing stops.34 Wet-wrap
dressings with diluted TCS (e.g. 1 : 3 for class II and 1 : 5 for
class III) are applied for up to 14 days (usually 3 days are suffi-
cient) and are a safe crisis intervention treatment, with tempo-
rary systemic bioactivity of the corticosteroid as the only
reported serious side-effects.75,76 Specialized nurse care is desir-
able to monitor wet-wrap treatment and to guide caregivers and
patients, as it is done in eczema schools.77
The ETFAD recommends wet-wrap treatment for AD patients
in flare, or with acute, oozing and erosive lesions.
Corticosteroids
Topical corticosteroids (TCS) are still the first-line anti-inflam-
matory treatment option in AD.5 There are different strengths of
TCS (mild, moderate, potent or super-potent) and different for-
mulations (creams, ointments, lotions or foams) available.78 The
choice of the TCS depends on the patient’s age, disease severity
and location of AD lesions. Super-potent TCS (group IV) are
not generally recommended for AD treatment, especially not in
children. For routine treatment of flares, once-daily application
of a potent TCS is sufficient, usually for 3–5 days. TCS should
be started as soon as the first signs of the flare appear. Itch is a
key symptom for evaluation of response to treatment, and taper-
ing should not be initiated before itch has disappeared.1 With
mild disease activity, monthly amounts in the mean range of
15 g in infants, 30 g in children and up to 60–90 g in adoles-
cents and adults, associated with a liberal use of emollients, gen-
erally allow a good maintenance with SCORAD values below
15–20.2
Topical corticosteroids should not be applied to the face every
day for more than one month, because it may induce skin bar-
rier fragility and rosacea-like perioral dermatitis. Intermittent
use will reduce the risk of side-effects. Applying TCS on the
inside of the thighs, upper arms and breasts (in females) for
longer periods may cause stretch marks, particularly in adoles-
cents. The risk of ocular complications with TCS seems to be
low. Potent and very potent TCS (groups III and IV) are more
likely to cause transient depression of adrenal function than
group I (mild) and group II (moderate strength) treatments.79
The most constructive way to use TCS and avoid steroid-re-
lated side-effects is not to spare them during acute flares, but
through early TCS intervention combined with consequent base-
line emollient skincare to stabilize the disease.80 Later on, proac-
tive therapy should be used in the long term (see proactive
therapy chapter below). The consequences of under treatment
might be more serious than those associated with TCS
treatment.81 The risk of inducing systemic side-effects is lower
with the use of the relatively new topical steroids with short half-
life, such as prednicarbate, fluticasone and mometasone. A
short-course, well-conducted systemic treatment may be safer
and more advisable than prolonged use of high potency TCS for
AD. Trials for TCS treatment in children less than 2 years old
are lacking as well as for long-term use of mid and high potency
TCS in paediatric populations.81,82 In practice, TCS are often
used in combination therapies (emollients, TCI, topical antibi-
otics, cyclosporine A83 or dupilumab84). Patients’ and healthcare
professionals’ fear of side-effects of corticosteroids (corticopho-
bia) is quite common and should be addressed.85 The education
of patients and healthcare professionals is required to increase
adherence to treatments.21
The ETFAD recommends using TCS according to standard
guidelines in combination with many other treatment modalities
including patient education.
Topical calcineurin inhibitors
TCI show quite good anti-inflammatory and very good antipru-
ritic effects, whilst lacking adverse effects associated with TCS
such as skin atrophy. TCI are especially useful in sensitive skin
areas and occlusive areas, and in patients who need long-term
treatment.78 Two TCI, tacrolimus ointment and pimecrolimus
cream, are licensed for topical AD treatment. The anti-inflam-
matory effects result from an inhibition of proinflammatory
cytokine production by T cells and mast cells, whereas part of
their antipruritic effects are attributed to a specific effect on
TRPV1 neurons in the skin.86 Applying the treatment twice a
day is more effective than just once for the treatment of flares.87–
90 The anti-inflammatory potency of 0.1% tacrolimus ointment
is similar to a TCS with intermediate activity,91 while the latter is
clearly more active than 1.0% pimecrolimus cream.92
Both TCI are safe to use and licensed for children aged 2 and
above, and for adults.93,94 Even long-term safety data from a 4-
and 10-year tacrolimus and a 5-year pimecrolimus study
exists.95,96 Off-label use in children below 2 years of age is very
common.94 The most frequently observed side-effect is a tran-
sient warmth sensation or transient burning at the application
site during the first days of application.87,92 It starts about 5 min
after each TCI application and may last up to one hour, but
intensity and duration typically decrease with twice daily appli-
cation within one week to zero.97 A few days of initial treatment
with TCS before switching to TCI may reduce the burning sensa-
tion, and an overlap period of one week may be advisable. A
transient flush sensation following alcohol uptake is observed in
few TCI-treated patients, which can effectively be blocked by
taking 500 mg acetylsalicylic acid about 30 min before alcohol
consumption. Patient education on these potential side-effects is
required for adherence.21
Viral skin infections such as eczema herpeticum or eczema
molluscatum have been observed during TCI treatment.98,99 In
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patients experiencing recurrent eczema herpeticum, continuous
prophylactic treatment with oral valaciclovir may be advis-
able.100 None of the TCI induces skin atrophy.101,102 This
favours their use over TCS in delicate body areas such as the eye-
lid region, the perioral skin, the genital area, the axilla region or
the inguinal fold and for topical long-term management. Clini-
cal data do not indicate an increased risk of the induction of
lymphoma or other types of malignancies,94,103 or photocarcino-
genicity,95,104,105 for TCI, but UV protection, e.g. with sun-
screens, is recommended for theoretical safety reasons.93,94
The ETFAD recommends first-line use of TCI in delicate body
areas, with preference for pimecrolimus in mild AD, and for
tacrolimus in moderate and severe AD and for long-term topical
treatment. Off-label use below the age of 2 years is also recom-
mended.
Tar derivatives – aryl hydrocarbon receptor agonists
Topical application of coal tar is one of the oldest therapies for
AD, with long-standing but constantly declining clinical use and
moderate efficacy.3 Coal tar may restore filaggrin expression and
counteract the Th2-mediated downregulation of skin barrier
proteins by aryl hydrocarbon receptor (AHR) activation and
STAT6 dephosphorylation, thus diminishing spongiosis, apop-
tosis and CCL26 expression in AD lesions.106 The cosmetic
acceptance of tar preparations is poor, but tar preparations may
be considered in selected cases, for example those with lichenifi-
cation. The use in infants is controversial.
Recently, a 12-week, double-blind, vehicle-controlled, ran-
domized study was performed using various concentrations of
tapinarof (GSK2894512; 5-[(E)-2-phenylethenyl]-2-(propan-2-
yl) benzene-1,3-diol), an AhR-modulating agent in adult
patients with AD (BSA 5%–35%).107 The most effective treat-
ment was the 1% formulation applied twice a day, with a statisti-
cally significant treatment success. The most frequent treatment-
emergent adverse events were folliculitis and contact dermatitis.
Tapinarof is currently not licensed in any country for AD or any
other indication.
Topical phosphodiesterase 4 inhibitors
Phosphodiesterase 4 (PDE4) is a key regulator of inflammatory
cytokine production in AD through the degradation of cyclic
adenosine monophosphate.108 A recent meta-analysis including
7 double-blind randomized clinical trials of topical PDE4 inhibi-
tors vs vehicle treatment for 1869 patients with mild-to-moder-
ate atopic dermatitis concluded that topical PDE4 inhibitors
were effective and safe for patients with mild-to-moderate
AD.109
The most extensively studied topical PDE4 inhibitor, crisa-
borole, was studied in two identically designed, vehicle-con-
trolled, double-blind studies (28 days) in patients aged 2 years
and older with mild or moderate AD. Despite a strong vehicle
effect, more crisaborole-treated than vehicle-treated patients
achieved an Investigator’s Static Global Assessment (ISGA) score
of clear or almost clear with ≥2-grade improvement.110 Cris-
aborole ointment had a low frequency of treatment-related
adverse effects over 48 weeks of treatment of patients with AD
observed in a long-term safety study.111 Clinical trials with crisa-
borole in very young children (3–24 months) and studies com-
paring the efficacy of crisaborole to TCS and TCI are running,
but the results are not published. Crisaborole is licensed in the
United States, but not marketed in the EU.
At present, no recommendation can be given regarding topi-
cal PDE4 inhibitors.
Proactive therapy
By tradition, topical anti-inflammatory therapy has been applied
to lesional skin only and has been stopped or tapered down once
visible lesions were cleared. This reactive approach has been
complemented by the proactive treatment concept, which is
defined as a long-term, low-dose, anti-inflammatory treatment
applied to previously affected areas of skin, in combination with
use of emollients on the entire body and an appointment sched-
ule for clinical control examinations.23 Proactive therapy will
prolong the time to relapse.32 The proactive, usually twice-
weekly topical treatment of previously affected areas is started
only after all visible lesions have successfully been treated, in
addition to daily ongoing emollient therapy for both previously
affected skin and unaffected skin.32 Clinical trial data are avail-
able for the TCS methylprednisolone aceponate and fluticasone
propionate for up to 3 months, and for tacrolimus ointment for
up to 1 year.112–115 As a rule, barrier disruption is lower with
proactive therapy than with daily application, as it is lower with
TCI than with TCS.116 Both TCS and TCI showed an antipru-
ritic effect, with TCI being superior to TCS.117 The cost-effec-
tiveness of proactive therapy with topical tacrolimus has been
demonstrated, as well as a beneficial effect on quality of life and
lower aeroallergen-specific IgE levels in patients using proactive
therapy.118,119 Clinical experience and indirect evidence from
many trials suggest that tacrolimus ointment, as well as TCS of
Niedner classes II and III, are good candidates for proactive
treatment, whereas pimecrolimus cream and TCS of Niedner
class I are less efficient.32
The ETFAD recommends the introduction of proactive ther-
apy with TCI or TCS in patients with moderate-to-severe AD.
Phototherapy
Phototherapy is a topical treatment option to improve skin
lesions, pruritus and sleeplessness in AD patients, with remission
periods up to 6 months and no documented serious short-term
side-effects.120 In AD, phototherapy affects several factors such
as the suppression of the antigen-presenting function of Langer-
hans’ cells, induction of antimicrobial peptides, the induction of
apoptosis of infiltrating T cells121, a reduction in the coloniza-
tion by S. aureus and Malassezia species122 and a reduced antigen
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presentation following an increased phototherapy-induced
thickness of the stratum corneum.123
Phototherapy is frequently used for the treatment of AD,
especially for the treatment of the chronic phase in adults.120
Phototherapy is usually part of a complex treatment plan, i.e. a
second-level treatment.3
UV treatments should not be used to treat acute, in particular
oozing, lesions as this will often result in a worse outcome.
Patients with acute flares should instead be treated with a stan-
dard regimen for some days before starting UV treatment.3 Due
to practical challenges, theoretical concerns and limited data on
the use of phototherapy in children with AD, phototherapy is
usually not considered in prepubertal children, although not
contraindicated.3,4 In practice, the limitations are the availability
of UV light machines, feasibility and lack of efficacy on lesions
on scalp and folds. Combined use of TCI with UV is still contro-
versial, even if the initial warnings of an increased skin cancer
risk have not been substantiated.105,124
Beside natural sunlight (NSL), phototherapy for AD may be
useful with different artificial light sources: broad-spectrum
UVB (280–315 nm), narrowband (nb-) UVB (311–313 nm),
broadband UVA (UVA) (315–400 nm), UVA1 (340–400 nm),
UVA1 cold light (with seawater baths) plus UVB (balneopho-
totherapy) and psoralen plus UVA (PUFVA). UVA1 photother-
apy can be applied as moderate-dose (MD) (50 J/cm2) and low-
dose (LD) (10 J/cm2) regimen, whereas high dose (HD) (130 J/
cm2) is not recommended anymore for AD treatment. Using
308-nm monochromatic excimer light allows the treatment of
only limited areas.125 Though blue light has been used for AD in
an uncontrolled trial,126 treatment with longer wavelengths has
not been carefully studied for AD and is therefore not recom-
mended.
nb-UVB is indicated for chronic moderate forms of AD and
seems to cause less erythema compared with broadband UV.
Medium-dose UVA1 appears to be similarly effective as nb-
UVB,127 but is more time-consuming. Concomitant treatment
with TCS, emollients and phototherapy should be considered in
order to reduce flare-ups.
UV light can also be combined with a prior (oral or topical)
administration of photosensitizing drugs (psoralens): the so-
called PUVA (photochemotherapy). All UV treatments and,
even more, photochemotherapy pose a long-term risk of devel-
opment of skin cancer, together with the proven prematurely
ageing of the skin.120 There are some data that individuals with
filaggrin deficiency are particular at risk.128,129
Photochemotherapy for AD treatment has largely been
abandoned due to its proven carcinogenicity and the fact that
most AD patients are young.3 Oral PUVA has a number of
side-effects, which may include nausea, headache, fatigue,
burning skin, itching and irregular skin pigmentation as well
as an increased risk of skin cancer,120 so the risk/benefit ratio
of full-body treatment is usually unfavourable. In contrast,
the risk/benefit ratio of topical PUVA for palms and soles is
usually favourable.
The ETFAD recommends concomitant nb-UVB or medium-
dose UVA in combination with TCS or selected systemic therapy
for the treatment of AD.
Allergen Immunotherapy in AD
The efficacy and safety of allergen immunotherapy (AIT) in AD
have been demonstrated in case reports, smaller cohort studies
and a few larger multicentre trials. It is evident that AIT may
improve the course of AD in selected patients rather than being
a general risk of deterioration of the disease as anticipated by
some patients and researchers.130 Favourable effects of AIT on
disease symptoms of AD appear to be higher if accompanying
relevant type I sensitizations are present, but only house dust
mite-sensitized patients have been studied in larger studies.131,132
Here, the data for subcutaneous immunotherapy are stronger
when compared to sublingual therapy and patients with severe
AD (SCORAD > 50) showed better results.132
Patients with a positive APT, a positive challenge reaction or a
history of eczema flares during the corresponding season, may
be preferred candidates for future studies on AIT with the elicit-
ing allergen. Regarding routine care, AIT is currently not recom-
mended as a general treatment option for AD, but may be
considered for selected patients with house dust mite, birch or
grass pollen sensitization and severe AD.5 Importantly, AIT may
well be used in AD when approved indications for this treatment
(allergic rhinoconjunctivitis or allergic asthma) exist in the same
patient.
The ETFAD does not recommend AIT as a general treatment
option for AD. However, AIT may be considered for selected
patients with house dust mite, birch or grass pollen sensitization,
who have severe AD and a history of clinical exacerbation after
exposure to the causative allergen or a positive corresponding
atopy patch test.
Antihistamines
Systemic antihistamines targeting the histamine 1 receptor
(H1R) are often used to reduce itch in acute AD flares, whereas
topical application has only been studied for doxepin in AD. A
few randomized controlled trials have been conducted which
have shown only a weak or no effect in decreasing pruritus in
AD.
Low-quality evidence indicated that H1R antagonists (H1RA)
might be effective as ’add-on’ therapy when compared to pla-
cebo.133 Due to this analysis, fexofenadine may lead to a small
improvement in patient-assessed pruritus, with probably no
clinically relevant difference in the amount of treatment used to
prevent eczema flares. Cetirizine and loratadine were not supe-
rior to placebo in terms of clinical signs or symptoms. Of note,
in a frequently cited controlled study, cetirizine has not shown
any effects on AD scores but a protective or inhibiting effect on
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associated urticaria in AD patients.134 Antihistamines are gener-
ally safe in use and may be tried to decrease pruritus and permit
sleep during flares, but particularly the first generation of anti-
histamines may affect sleep quality. Therefore, long-term use of
sedative antihistamines is not recommended. In fact, a recent
retrospective study attributed a higher rate of attention-deficit/
hyperactivity symptoms (ADHS) in children with AD and a his-
tory of medication with antihistamines.135 Ongoing studies
focus on the blockade of alternative histamine receptors such as
H4RA, which may be more important in AD.136,137
In conclusion, there is not enough randomized control trial
evidence to demonstrate the efficacy of topical antihistamines,
including doxepin in the treatment of itch in AD.
The ETFAD does not recommend the general use of first- or
second-generation H1RA for the treatment of pruritus in AD.
H1RA may be tried for the treatment of pruritus in AD patients,
if standard treatment with TCS, TCI and emollients is not suffi-
cient. Long-term use of sedative H1RA in childhood is not rec-
ommended.
Systemic anti-inflammatory therapy
Systemic therapy is necessary if AD cannot be controlled suffi-
ciently with appropriate topical treatments and UV light ther-
apy. It can also be useful to reduce the total amount of TCS in
patients who need large amounts of potent TCS for vast body
areas over prolonged periods to control their AD.138 Before
starting a systemic treatment, it is important to rule out differen-
tial diagnoses such as cutaneous T-cell lymphoma, potential trig-
ger factors such as allergic contact dermatitis and behavioural
and educational reasons for poor responses.74,139 Until recently,
rather broad-acting immunosuppressants, such as systemic cor-
ticosteroids (SCS), cyclosporine A (CyA), azathioprine (AZA),
mycophenolate mofetil (MMF), enteric-coated mycophenolate
sodium (EC-MPS) and methotrexate (MTX), were the only sys-
temic treatment options for difficult-to-treat AD.140 These sys-
temic immunosuppressants can roughly be divided into two
groups: SCS and CyA have a rapid onset of action and can be
used to treat flares of AD or to bridge the time until onset of
action of slow-acting systemic immunosuppressants such as
MTX, AZA and MMF/EC-MPS. Dupilumab is the first biologic
specifically licensed for AD, and many other biologics and small
molecules are in advanced stages of clinical development.141 The
following recommendations for systemic drugs are based on
expert opinions and medical considerations and may differ from
the legal licensing status and access routes, which are not uni-
form in European countries.
Systemic corticosteroids
Systemic corticosteroids (SCS) are rapidly effective, but have a
largely unfavourable risk/benefit ratio.3 SCS should only be used
for 1–2 weeks for severe acute exacerbations due to the many
long-term side-effects. A typical regimen for severe acute
exacerbations would be methylprednisolone maximal 0.5 mg/
kg/day for 1–2 weeks and tapering over 1 month.3 Short courses
of SCS without adequate tapering can lead to high rates of
relapse or rebound of the disease. In severe chronic cases, start-
ing another oral immunosuppressive therapy while tapering the
SCS should be considered. SCS must not be used for long peri-
ods of time due to significant risk of severe side-effects.3
Cyclosporine A
Cyclosporine A (CyA) is frequently used and very effective for
AD in both children and adults.142 It is used at 3–5 mg/kg/day,
divided into a morning dose and an evening dose. The dosage
should be started at 5 mg/kg/day and can usually be tapered
after 4–6 weeks to 2.5–3 mg/kg in the maintenance phase. CyA
has a narrow therapeutic index and requires close monitoring of
blood pressure and signs of renal impairment, especially in
elderly patients. CyA is approved for systemic treatment of AD
in adults in most European countries.142 CyA may be used off-
label for children or pregnant females.6 Treatment duration usu-
ally varies from 3 months to 1 year, but some patients tolerate
much longer low-dose CyA treatment very well.143 CyA is usu-
ally considered as the first-line option for patients requiring
immunosuppressive treatment,142 although the drug survival for
CyA is much shorter than for MTX.143
Methotrexate
Methotrexate (MTX) has a slow onset of action. The recom-
mended therapeutic doses are between 10 and 25 mg once
weekly in adults and between 0.2 and 0.5 mg/kg/week in chil-
dren (maximum dose 25 mg/week).3 MTX is about equally
effective as AZA and CsA in adults and children. The maximal
clinical efficacy of MTX is reached after 8–12 weeks. Some
reports suggest that in adult patients, higher dose of MTX (be-
tween 15 and 25 mg/week) could be used to reach maximum
efficacy. Moreover, MTX showed good long-term effectiveness
just like AZA. MTX is often well-tolerated and available for oral
and subcutaneous administration. Infections, gastrointestinal
disturbances and, in rare cases, myelotoxicity may limit the use
of MTX. Each MTX cycle should be followed by a folic acid sub-
stitution.144–147 MTX is hepatotoxic and teratogenic, and
women of childbearing potential must use effective contracep-
tion during therapy.6
Azathioprine
Azathioprine (AZA) has a slow onset of action, as the maximal
clinical efficacy is reached after 8–12 weeks. A starting dose of
50 mg/day for 1–2 weeks is recommended in adults. Depending
on acute adverse events such as gastrointestinal side-effects, liver
enzyme elevation or haematological abnormalities, the dose can
usually be increased to 2–3 mg/kg/day. Low thiopurine methyl-
transferase (TPMT) activity is associated with an increased
myelotoxicity of AZA, but TMTP activity screening tests can
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identify patients at risk before starting the treatment. If this test
is not available, treatment can be started with half the dosage,
whilst monitoring for side-effects. Although most clinical trials
are of short duration, there is evidence that AZA is effective and
safe for the treatment of AD for up to 5 years. However, drug
survival is mainly limited due to side-effects.145,148 AZA
increased the risk of non-melanoma skin cancer and lymphoma
in inflammatory bowel disease patients.95,104,149,150 AZA may be
used in children. In pregnant females, AZA should only be used
on strict indication.6,151,152
Mycophenolate mofetil
Mycophenolate mofetil (MMF) has a slow onset of action. A
dose of MMF at 2 g/day and EC-MPS at 1440 mg/day is com-
monly used. However, enteric-coated mycophenolate sodium
(EC-MPS) is equally effective as CyA as maintenance treatment
in patients with AD. MMF may be used in children,5,152 and the
recommended dose is between 20 and 50 mg/kg/day. Mild gas-
trointestinal side-effects and haematological abnormalities are
frequently observed during MMF treatment, but the general
security profile seems to be quite favourable, making it an unli-
censed but clinically useful treatment alternative for severe AD
patients, especially for maintenance therapy. MMF and EC-MPS
are both teratogenic, and women of childbearing potential must
use effective contraception during therapy.6,148,152–154
The ETFAD recommends an initiation of classical immuno-
suppressive therapy with CyA, MTX, MMF or AZA only if topi-
cal treatment is not an option. The treating physician should
have experience with these substances, and the choice of drug
should consider all relevant patient- and drug-related factors
including the patient’s comorbidity, expected onset of efficacy,
planed duration of treatment and licensing status of the drug.
JAK Inhibitors in clinical trials
Janus kinase (JAK) inhibitors are fast-acting drugs, which sup-
press a wide range of pathways. There are multiple lines of evi-
dence that the JAK-STAT signalling pathway plays a major role
in AD. An advantage of inhibiting JAK1 is that it covers multiple
cytokines involved in the pathophysiology of AD, including IL-
4, IL-13, IL-31, TSLP and IL-22. A JAK1 inhibitor may therefore
be effective where a more selective biologic such as Th2 blockers
has been insufficiently effective, but more side-effects might be
observed. Several oral JAK inhibitors are currently under investi-
gation for the management of AD. More study data have been
presented at congresses than have appeared in full publications
in peer-reviewed journals. Some JAK inhibitors are already
licensed for rheumatoid arthritis.
Baricitinib is an oral selective JAK1 and JAK2 inhibitor
licensed for rheumatoid arthritis in many European countries.
The results of three phase 3 studies investigating oral baricitinib
at 1, 2 and 4 mg daily for the treatment of AD are published.155
Two placebo-controlled monotherapy studies were conducted
without the addition of TCS (except as rescue therapy). 36% of
patients achieved EASI 75 with baricitinib 4mg daily at week 16
without censoring for TCS rescue. In the third study, 47.7% of
patients achieved EASI 75 when baricitinib 4mg daily was added
to standard care TCS at week 16.155 The most frequent adverse
events were upper respiratory tract infections, headaches and an
increase in blood creatine kinase.
Upadacitinib (ABT-494), an oral selective JAK1 inhibitor,
showed reduction in pruritus as early as week 1 and improve-
ment of the extent and severity of skin lesions as early as week 2
in a phase 2b trial.156 At week 16, 69% and 50% of the patients
achieved EASI 75 and EASI 90, respectively, with 30 mg daily.
The most common relevant adverse events were upper respira-
tory tract infections and acne.156
Abrocitinib (PF-0496582) is another oral selective JAK1 inhi-
bitor, which showed positive results in a phase 2b study.156
Reduction in the EASI score was 82.6% for patients receiving
200 mg daily. 65% and 52% of the patients achieved EASI 75
and EASI 90, respectively, with 200 mg daily.157 The most fre-
quently reported, relevant adverse events were upper respiratory
tract infections. Dose-dependent decreases in platelet count were
observed but would recover back towards baseline levels after
week 4.
JAK inhibitors are promising, fast-acting and potent therapies
for the treatment of adult and adolescent AD. Dose selection for
chronic treatment and long-term safety profiles will be impor-
tant to assess, considering the potential risk of malignancies,
serious infections and venous thrombosis. The more selective
JAK1 inhibitors targeting only JAK1 may have less unwanted
drug effects than the less specific JAK inhibitors.
The ETFAD recommends checking on a regular basis all
upcoming information on JAK inhibitors, as the licensing of
new drugs for the treatment of AD is likely.
Alitretinoin
Alitretinoin offers anti-inflammatory and anti-proliferative
effects. One large trial involving 1032 chronic hand eczema
patients,158 about one-third of which are probably atopic hand
eczema patients, as well as a small case series of six AD
patients159, indicate that this teratogenic drug is effective in ato-
pic hand eczema and that bystander improvement of extrapal-
mar AD lesions is likely. Alitretinoin may be considered in adult
atopic hand eczema patients unresponsive to TCS,3 but is strictly
contraindicated in pregnant women.6
Maternal and paternal exposure to oral
immunosuppressive drugs
The maternal benefit of oral immunosuppressive drugs in
expecting AD patients must always be weighed on an individual
basis against possible adverse effects such as spontaneous abor-
tion, prematurity, low birthweight, adrenal insufficiency, infec-
tions and teratogenicity.6 Treatment with CyA and SCS is well
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possible during pregnancy, but the unfavourable risk/benefit
ratio of SCS remains.3 MTX, alitretinoin, MMF and EC-MPS are
strictly contraindicated in pregnancy. Continuation of AZA
treatment (halved dose) is considered possible on strict indica-
tion.6
Detailed ETFAD recommendations for the treatment of AD
in pregnant women have been published in 2019.6
The relationship of paternal use of oral immunosuppressive
drugs before fathering and congenital abnormalities is less clear
than the effects of maternal use. Although studies are often
small and of poor quality, several guidelines recommend for
menusing AZA or MPA to adequately use contraceptive mea-
sures during treatment and for three months thereafter.160 It is
recommended to wait three months after stopping MTX before
fathering.
Biologics
Although AD is considered to involve multiple immune path-
ways potentially underlying different disease subtypes, a strong
activation of type 2 immune responses, driven by innate type 2
lymphoid cells and type 2 T-helper cells with their signature
cytokines IL-4, IL-5 and IL-13, appears to be a dominant mecha-
nism.141 Targeting type 2 pathways is therefore a reasonable
therapeutic strategy.
Dupilumab
Dupilumab is the first biologic that has been approved as first-
line treatment for moderate-to-severe AD in patients 12 years
and older in the United States and in Europe. It is a fully human
monoclonal antibody against IL-4Ra that blocks both IL-4 and
IL-13 signalling. In randomized controlled trials of up to
52 weeks, treatment with dupilumab as monotherapy or in com-
bination with TCS improved multiple measures of AD signs and
symptoms as well as health-related quality of life.161–165 Data
from registries and real-world case series showed comparable
response rates.166–168
The safety profile of dupilumab is favourable with conjunc-
tivitis and blepharitis being the most frequent side-effect
observed in up to 22.1% of dupilumab users in clinical trials169
and up to 38.2% in real-world settings.167 Most conjunctivitis
cases are transitory and can be successfully managed without
dupilumab withdrawal.169 Treatment options for dupilumab-as-
sociated conjunctivitis include artificial tears for mild cases,
topical corticosteroid fluorometholone 0.1% eye drops, topical
calcineurin inhibitor ointment applied to the eye lids for moder-
ate, and eye drops or ointments containing cyclosporine or
tacrolimus for severe forms.170–172 In addition, a paradoxical
head and neck erythema, also known as red face syndrome, may
develop with prolonged use of dupilumab, but can be treated
with topical antimycotic or anti-inflammatory prepara-
tions.173,174 Noteworthy and in contrast to many other biologics,
there appears to be no need for laboratory monitoring.175
Dupilumab should be combined with daily emollients and may
be combined with topical anti-inflammatory drugs as needed.84
Conventional systemic immunosuppressants may be continued
in the first weeks after initiation of dupilumab treatment until
the full clinical outcome is reached.166 Dupilumab is currently
approved for adults and children aged 12 years and above. Phase
III data on children aged 6 years and above are available, and a
timely approval for this age group is expected. The approval of
dupilumab for certain forms of severe asthma and severe chronic
rhinosinusitis with nasal polyposis by the EMA may also be rele-
vant when choosing a drug.
The ETFAD recommends dupilumab for the treatment of
patients aged 12 years or over with moderate-to-severe atopic
dermatitis, who are candidates for systemic therapy.
Biologics in clinical trials
Many other biologics, which interfere with different cytokines
and signalling pathways, are currently being tested in phase 2
and phase 3 trials, e.g. tralokinumab (anti-IL-13), fezakinumab
(anti-IL-22), etokimab (anti-IL-33), nemolizumab (anti-IL-
31Ra) and tezepelumab (anti-TSLP),141 and may become avail-
able in the next years.
Recently published phase 2 studies demonstrated that mono-
clonal antibodies blocking IL-13 (lebrikizumab, tralokinumab)
are effective in patients with moderate-to-severe AD.176,177 By
applying fezakinumab, an anti-IL-22 antibody, a significant
decline of disease severity scores (SCORAD, affected body sur-
face area and investigator global assessment) could be achieved
and a pathogenic role for IL-22 in severe AD was demon-
strated.178 Two-phase 2 studies with nemolizumab, the anti-IL-
31 receptor antibody, showed a large reduction in pruritus and
in parallel improvement of clinical signs of AD underlining the
role of the itch-scratch cycle.179,180 The improvement of pruritus
and dermatitis scores from baseline is maintained or may even
increase upon long-term treatment (up to 64 weeks) with nemo-
lizumab.181 The difficult-to-treat subgroup of patients with
prurigoform AD may profit especially well from nemolizu-
mab.182 A proof-of-concept study reported a rapid and sustained
effect of a single administration of etokimab, an anti-IL-33 mon-
oclonal antibody, in patients with AD.183
The ETFAD recommends checking on a regular basis all
upcoming information in this field, as the licensing of new drugs
for the treatment of AD is likely.
Antibacterial and antimycotic therapy
AD patients are more susceptible to secondary skin infections
which tend to generalize, especially with S. aureus,Malassezia furfur
and herpes simplex virus.184,185 The inflammatory micro-milieu
initiated by thymic stromal lymphopoietin (TSLP), IL-4 and IL-13
downregulates important cutaneous antimicrobial peptides such as
cathelicidin LL-37, dermcidin and human b-defensins HBD-1,
HBD-2 and HBD-3.184,186 The understanding of colonization and
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2020
14 Wollenberg et al.
infection in AD has largely increased by detailed investigation of
the human microbiome. A S.aureus-driven loss of diversity of the
cutaneous microbiome is significantly associated with flares of AD,
but not if patients have followed a proactive therapy regimen
before the flare.187 In up to 90% of AD patients, even non-lesional
skin is extensively colonized by S. aureus. Many commensal bacte-
ria, such as S. epidermidis, produce inhibitors that decrease S. aur-
eus growth.188 Strains of S. aureus found on AD patient’s skin are
different from strains isolated from the nasal carriers in normal
population.189
S. aureus is a major trigger of AD, as inflammation is triggered
through the release of toxins with superantigenic properties.
These superantigens enhance T-cell activation in the skin, and
also increase the expression of IL-31, leading to pruri-
tus.190 Scratching favours binding of S. aureus to the skin, and
the increased amount of S. aureus-derived ceramidase aggra-
vates the skin barrier defect. Moreover, superantigen production
increases the expression of alternative glucocorticoid receptors
that do not bind topical corticosteroids, which leads to steroid
resistance.191 Biofilm formation by AD-associated staphylococci
may play a major role in the occlusion of sweat ducts leading to
inflammation and pruritus.192
Antibacterial therapy
Regular cleansing of the skin with syndets, topical antiseptics
and antibiotics, systemic antibiotics and functional textiles have
been used to reduce S. aureus on AD patients’ skin. In clinical
practice, a selection must be done based on clinical aspects, as all
of these measures have strengths and weaknesses. Most interven-
tions aim at reducing the burden of S. aureus.
Newly developed emollients include active compounds that
influence the microbiome of AD with bacterial lysates from
Aquaphilus dolomiae or Vitreoscilla filiformis species.193 These
are usually well-tolerated and improve the epidermal barrier as
an added value, but the antibacterial effect against S. aureus
seems low compared with antiseptics or systemic antibiotics.
Physicians should not forget that a proper, well-conducted anti-
inflammatory therapy with TCI or TCS will also reduce the colo-
nization with S. aureus.
Both topical antiseptics and topical antibiotics may reduce
S. aureus and other potentially helpful bacteria from the
skin, but bacterial resistance and contact allergy are an issue.
There is no clear benefit of antiseptic bath additives, antisep-
tic soaps or other antimicrobial agents added to topical ther-
apies in non-infected atopic dermatitis, as evidenced in a
large systematic review of 26 studies including 1229 partici-
pants.194 Nevertheless, if there is no response to topical TCS
or TCI, or evident infection, the use of topical antiseptics
may be considered. These are preferred over topical antibi-
otics, as the development of bacterial resistance is less likely.
A more recent systematic review published in 2017 con-
firmed these results.195
Sodium hypochlorite 0.005% has antiseptic properties and
enhances in addition epidermal thickness and proliferation.196
Its intermittent use showed a significant decrease in AD sever-
ity.197 The addition of 100 mL of normal sodium hypochlorite
household bleach (most come as 5% solution) to a full bath of
100-L tap water is the usual procedure. Potassium perman-
ganate, which is the classical antiseptic substance, may stain
bathtubs and patients and is difficult to get in some countries.
Impetigo is easily diagnosed by the yellow crusts and can be
treated with fusidic acid, topical mupirocin or topical retapa-
mulin for 5 days.198 The high rate of S. aureus resistance against
fusidic acid in Europe compared with the United States reflects
the more frequent use in Europe.199
Systemic antibiotics should only be used in case of apparent
and extensive bacterial superinfection. Based on the current
resistance spectra, cephalexin or another first-generation cepha-
losporin can be recommended.200 Children with AD seem to
have a much lower rate of community-acquired methicillin-re-
sistant S. aureus infection compared with the general paediatric
population.201
Hidden sources of bacteria are cream and ointment contain-
ers, of which up to 53% are contaminated by bacteria, in 25%
by S. aureus. Thus, the following recommendations seem to be
useful 202: (i) keep open moisturizers in refrigerator; (ii) use
pumps or pour bottles rather than jars; (iii) avoid direct contact
with hands and decant; and (iv) avoid sharing personal hygiene
items.
The ETFAD recommends considering topical antiseptic drugs
and antiseptic baths in addition to an adequate anti-inflamma-
tory treatment with TCS and TCI, if clinical signs of strong colo-
nization or bacterial superinfection are present. A long-term
application of topical antibiotics is not recommended due to the
risk of increasing resistances and sensitizations. A short course
of systemic antibiotics, such as a 1st-generation cephalosporin,
may be considered in AD patients with widespread and severe S.
aureus infection.
Antimicrobial textiles
Various functional textiles with antimicrobial properties and dif-
ferent qualities have been on the market for years and have been
worn for either 24 h or overnight only. Silver-coated textiles are
assumed to release low amounts of silver ions to the skin, where
a moderate antiseptic effect is observed. The physical stability
and resistance to repeated washings of these different textiles are
quite heterogeneous.203 AEGIS-coated silk textiles are another
product line in this niche.
Silver-impregnated textiles have shown significant antimicro-
bial activity, as well as improvement of localized SCORAD in an
unblinded, side-to-side controlled clinical trial.204 In patients with
uninfected AD, the use of silver-impregnated textile compared
with cotton underwear did not reduce AD severity.205–207 How-
ever, some functional textiles (silver-coated, acid-coated and silk
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2020
ETFAD - Diagnosis and treatment of atopic dermatitis 15
textiles) as well as chitosan, a natural biopolymer with
immunomodulatory and antimicrobial properties, may possibly
improve AD manifestations, as they decrease skin colonization
by S. aureus and reduce itch.208 Some of these newer options are
still under investigation regarding the safety of silver-coated tex-
tiles in infants and toddlers. AEGIS-coated silk textiles did not
show clinical benefit in a well-controlled, multicentre clinical
trial.209
More recent studies evaluated these antimicrobial textiles in
real life. Some silver-impregnated textiles lose their antimicro-
bial activity after 70 laundry cycles, whereas some others remain
intact and still effective after 150 laundry cycles.203 A second
study described that this kind of textiles was unable to modify
skin colonization with S. aureus under practical wear conditions
(dry textiles), but the effectiveness could be enhanced by wetting
the textiles. The authors found also that some moisturizing
cream remains on the fibres after laundry.210 In conclusion, effi-
cacy and stability have been demonstrated for some silver prod-
ucts, and all silk and silver products are considered safe.
The ETFAD recommends considering high-quality silver gar-
ments to AD patients tending to strong colonization or infection
with S. aureus.
Antiviral therapy
Viral infections with herpes simplex virus, varicella zoster virus,
molluscum contagiosum virus, smallpox virus and Coxsackie
virus occur more frequently in AD patients than in healthy indi-
viduals, with a tendency to cause disseminated, widespread dis-
ease.185
Eczema herpeticum (EH), a disseminated herpes simplex virus
(HSV) infection, is a potentially lethal complication of AD that
requires immediate medical action. Patients, mostly children,
present with disseminated, distinctly monomorphic vesicles,
fever and lymphadenopathy. Complications such as keratocon-
junctivitis, meningitis and encephalitis are rarely encountered.100
A depletion of plasmacytoid dendritic cells, a failure of upregula-
tion of the antimicrobial peptide LL-37 and an unmasking of the
entry receptor nectin-1 by lesional spongiosis are considered rel-
evant for the pathogenesis of EH.100,211 IL-4 and IL-13 suppress
keratinocyte expression of the antimicrobial peptide LL-37,
which has a potent antiviral activity against HSV.212 Some
genetic variants of transcription factor STAT6, which regulates
IL-4, are associated with EH in AD patients.213 Predisposing fac-
tors of EH are early onset of AD, severe or untreated forms of
AD, filaggrin deficiency, high total serum IgE level, elevated
allergen-specific IgE and peripheral eosinophilia.185,214 Almost
all EH patients are of the extrinsic AD subtype 100, and Th2
polarization of HSV-1 specific T cells has been shown in EH
patients.215 Pretreatment with TCS does not seem to imply an
increased risk of developing EH, whereas TCI may do so and
should be paused for some weeks.216 Mainstay of EH therapy is
a systemic treatment with aciclovir or valaciclovir.213 Treatment
should be started immediately once the diagnosis is clinically
suspected.3 Patients with AD have a fourfold increased risk of
developing ocular HSV infections. For AD patients with a his-
tory of HSV keratitis, a long-term oral antiviral prophylaxis may
be advisable because of the potential vision loss risk due to scar-
ring cornea.217 The rate of localized HSV infections in AD
patients treated with dupilumab is higher compared with pla-
cebo, but lower for EH and varicellazoster virus infection.218
Varicellazoster virus (VZV)infection in an immunocompetent
child is usually a mild, self-limited disease. This infection is
known to facilitate secondary local or systemic bacterial infec-
tion, which is cause for particular concern in AD children. The
safety and efficacy of VZV vaccination in AD children are well-
established.219 Moreover, in children with AD, common child-
hood immunization in the first year is not associated with an
increased risk of more severe AD or allergic sensitization; also,
immune response to VZV vaccine is comparable to healthy chil-
dren.220 Therefore, parents of atopic children should be encour-
aged to follow their local vaccination plan including VZV
vaccination.
Molluscum contagiosum virus (MCV) infection is in general
benign and self-limited, but dissemination is frequent in AD
patients, and therefore, treatment is recommended. MCV infec-
tion seems to be a trigger for disease onset or flare of AD in chil-
dren with a positive family history of AD.221 A large variety of
topical treatments have been reported such as cantharidin,
potassium hydroxide, tretinoin cream, topical cidofovir and
others.222 Physical therapies including cryotherapy and curettage
are also effective, but not always well-tolerated in paediatric
patients.185 Topical treatment of AD with TCS and TCI may be
continued during MCV infection.
Eczema vaccinatum (EV) is a complication of smallpox vacci-
nation known to occur in AD patients. The vaccinia virus dis-
seminates and causes an extensive rash and severe systemic
illness with a mortality rate estimate at 5%–40%.223 Therefore,
smallpox vaccination is contraindicated in patients with a his-
tory of or currently active AD.224 The existence of an attenuated
vaccine and three antiviral drugs, in addition to vaccinia
immunoglobulin, provides means of preventing or treating
EV.225,226 Should a smallpox outbreak necessitate an emergency
mass vaccination, the choice of vaccination strategies has to be
determined by policymakers.
Eczema coxsackium (EC) is a disseminated form of Coxsack-
ievirus infection mostly occurring in children with active AD
lesions. The Coxsackievirus A6 strain leads to atypical disease
manifestations, which are classified as diffuse form (lesions
extended to the trunk), acral form (lesions with a mainly acral
distribution) or eczema coxsackium (disseminated lesions on
pre-existing eczematous areas).227 Symptomatic treatment
includes use of TCS and wet-wrap therapy.228,229
The ETFAD recommends following all regional vaccination
programmes including the VZV vaccination as recommended.
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Parents of atopic children should be encouraged to fully immu-
nize their children. The denial of vaccination because of diag-
nosed AD is a common misconception possibly leading to fatal
consequences (see chapter: general measures). Eczema her-
peticum should be treated upon suspicion immediately using
systemic antiviral therapy, such as systemic acyclovir or valaci-
clovir.
Antifungal therapy
Malassezia spp. is a commensal on healthy human skin, but is
attributed a pathogenic role in AD, as it may interact with the
local skin immune response and barrier function. There is evi-
dence for a molecular mimicry between fungal and human
superoxide dismutase and thioredoxin proteins, which may con-
tribute to the pathogenesis of AD.230
Several randomized, placebo-controlled trials investigated the
benefit of topical or systemic antifungal treatment for AD
patients.231,232 The ambiguous results of these clinical trials
might be attributed to a selection bias. It can be speculated that
antifungal therapies are more effective in certain subgroups of
AD. It seems, for example, that antifungal therapy shows benefi-
cial effects in patients with a head–neck-type distributed AD and
detectable IgE-mediated sensitization against Malassezia.233 Sen-
sitization against this skin-colonizing yeast correlates with dis-
ease activity.234 The most common class of antifungal drugs
prescribed for AD patients are azoles such as ketoconazole and
itraconazole, which have also some anti-inflammatory proper-
ties.232
The ETFAD recommends considering antifungal treatment
with either topical ketoconazole or ciclopirox olamine for
patients suffering from atopic head–neck dermatitis, and partic-
ularly for those with known IgE-sensitization to Malassezia spp.
Complementary medicine for the treatment of AD
Complementary medicine describes a wide variety of healthcare
practices used alongside standard medical treatment. Examples
of complementary medicine include alternative health
approaches such as traditional Chinese medicine, homeopathy
and naturopathy.5 Many patients with AD, in some studies over
50%, have used complementary medicine for primary or adjunc-
tive treatment.235,236
There are an increasing number of trials studying complemen-
tary medicine for the treatment of adults and children with AD.237
The most frequently used modalities are herbal medicine, vita-
mins, Ayurveda, naturopathy, homeopathy and traditional heal-
ing.237 Most studies are small and with low methodologic quality.5
Many studies do not report adverse effects in a proper way and
safety often remains unclear due to insufficient reporting.237 It
should be noted that kidney failure and liver damage have been
reported in association with traditional Chinese medicine.238 A
Cochrane review published in 2013 included 28 randomized con-
trolled trials comparing Chinese herbal medicine (CHM) to
placebo. The authors could not find conclusive evidence that
CHM taken orally or applied topically to the skin could reduce the
severity of eczema in children or adults.239 Another Cochrane
review showed that oral borage oil and evening primrose oil lack
effect in eczema.240 The effect of n-3 (or omega 3) long-chain
polyunsaturated fatty acid supplementation in pregnant or breast-
feeding women on allergy outcomes in their children was assessed.
For any allergy, no clear differences were seen in children between
12 and 36 months, nor beyond 36 months of age.241
No evidence-based recommendations can be made from the
available literature.238 There is a great need for higher-quality
studies to guide patients as well as clinicians. Well-designed ran-
domized trials are necessary to confirm a beneficial effect and to
establish safe use. Future studies should be designed as double-
blinded, placebo-controlled trials, with sufficient power and
reported according to the CONSORT (Consolidated Standards
for Reporting Trials) statement.242,243 It is also important that
the core outcome set and core outcome instruments are chosen
in accordance with the harmonizing outcome measures for
eczema.244,245
The ETFD does not recommend complementary medicine for
the treatment of AD.
Vitamins and probiotics
The role of vitamin D and the vitamin D receptor (VDR) in AD
has been studied in three single centre randomized placebo-con-
trolled studies including a total of 142 patients. One study found
a significant clinical effect, but concomitant routine treatment
was allowed and not registered.246 Better-designed studies did
not find a beneficial effect of vitamin D supplementation on AD
manifestations.247-249 A recent systematic review, focused on the
effects of vitamin D levels and supplementation in children with
AD, confirmed a link between serum vitamin D levels and AD
severity, but only weak evidence was found supporting improve-
ment of AD with vitamin D supplementation.250 Hence, supple-
mentation of vitamin D is useful neither for treatment nor for
prevention of AD.251
Treatment regimens with probiotics aim to modulate the
microflora in the gut in order to stimulate the immune
response towards an allergy-protecting, T-helper 1-biased
immune reaction.252 There are several studies on the thera-
peutic effects of probiotics, but recent meta-analyses on the
effect of probiotics in pregnant women253 and in children254
do not demonstrate convincing effects of this treatment
modality compared with earlier meta-analyses.255,256 In a
recent Cochrane review assessing the effects of probiotics for
treating patients of all ages, the authors concluded that com-
pared to no probiotics, currently available probiotic strains
probably make little or no difference in improving patient-
rated eczema symptoms.257
The ETFAD does not recommend vitamin D or probiotics for
the treatment of AD.
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Specific considerations for children
The anatomical and pathophysiological peculiarities of children,
such as an incomplete skin barrier, a higher surface-to-body
weight ratio, a less experienced immune system – together with
the fact that many drugs effective for AD are not licensed for
them – result in special considerations and treatment rules for
young AD patients, especially for those aged 2 years and
younger. The larger surface area-to-body weight ratio in infants
can result in an up to 2.7 times higher systemic exposure which
implies a greater risk of intoxication.
The clinical presentation of infantile AD shows different
predilection sites and a tendency towards exudative lesions,
especially on the cheeks. Establishing a diagnosis of AD may be
difficult in this age group, because the classic diagnostic criteria
cannot be applied. In early-onset severe AD (<3 months), some
primary immunodeficiency syndromes such as Omen syndrome,
selective IgA deficiency, hyper-IgE syndromes and Wiskott–
Aldrich syndrome, some genetic disorders with an impaired bar-
rier function such as Comel–Netherton syndrome and peeling
skin syndrome, and some inherited metabolic diseases such as
biotin deficiency or phenylketonuria may be differential diag-
noses.258
Stress and conflicts in the family may trigger AD in young
children. Flares are associated with contact to non-familiar pets,
swimming in chlorinated pools and direct skin exposure to wool
(except superfine merino wool259) and nylon textiles.260 Preven-
tion and early recognition of atopic respiratory diseases and food
allergies are important during childhood and adolescence. In
children, food allergies triggering an exacerbation are more com-
mon than in adults. For small children, cow’s milk protein and
hen egg are the most common relevant allergens. In adolescents,
pollen-associated food allergens are more important. Food aller-
gies in young children are often transient, making follow-up
investigations necessary to assess the development of toler-
ance.261 Attention-deficit hyperactivity disorder (ADHD) and
autistic spectrum disorder (ASD) have been identified as possi-
ble comorbidities of AD.262
The principles of topical treatment are the same as in adults,
but are adapted with respect to an increased absorption and
altered surface-to-body weight ratio. The use of weaker TCS
(classes 1 and 2) in small children is common practice of many
dermatologists and paediatricians. Especially critical areas in
infants are the diaper area, the face and the scalp. An increased
use of TCI to spare TCS is widely advocated due to the ever-in-
creasing experience and long-term safety data with the substance
class.32,93 The off-label use of both TCIs in children under
2 years of age has been considered appropriate in the latest
European Guideline on Treatment of AD, based on good-quality
long-term safety data recently published for TCI in infants.4,95,96
Hypoallergenic topical preparations should be prescribed in
children with AD, as these have a significantly higher risk of
developing contact allergy to components of skincare products
than children with healthy skin.263 Glycerol as a moisturizer in
emollients is better tolerated than urea in children under 5 years
of age. Urea is a good emollient ingredient if used at 5% or less.
It is not only a humectant, but also induces the expression of
NMF ingredients in the skin. Sophisticated emollients may con-
tain urea, glycerol and ceramides. There are good data from the
AD flare prevention trials on tolerability. Topical drugs leading
to severe side-effects include salicylic acid and disinfectants con-
taining alcohol.264
Systemic treatment for children is administered on an indi-
vidual patient basis in severe cases only, and there is no con-
sented standard treatment for the substances or the duration.
The most commonly used anti-inflammatory drug in Europe
was CyA, followed by SCS and AZA.265 Recently, low-dose
MTX was shown to have a good safety profile in chil-
dren,266,267 even for long-term treatment,147 and an effective-
ness comparable to CyA.268 Difficult-to-treat nummular
forms of AD in children have also responded to MTX treat-
ment.269 Most systemic treatment of children and adolescents
is expected to shift to dupilumab, once the expected licence
for children is obtained.
Nocturnal pruritus is a common problem in medium-to-sev-
ere AD. A recent Cochrane Review concluded that there is no
consistent evidence for the effectiveness of oral H1 antihis-
tamines.133 Sedating H1 antihistamines may be tried for a short
period in acute exacerbations, when sleep disturbances persist
despite TCS and emollient use,270 but long-term use is not rec-
ommended.
Vaccinations, including those against measles, are generally
safe in hen’s egg-allergic AD patients,271 the only restriction
being the quality of skincare to avoid superinfection at injection
sites. Though smallpox vaccination was contraindicated in chil-
dren with AD to avoid eczema vaccinatum,224 vaccinations
against varicella are recommended to avoid severe cutaneous
viral infections.4
Therapeutic parent and child education (’eczema school’) is
an integrated part of AD management and especially valuable
for reducing AD symptoms.77,272 Written treatment instructions,
such as the ’Personalized Written Action Plan for Atopics’, may
be very useful.273 For treatment adherence, it is important to
establish a good relationship with the parents and consider the
burden of disease they carry.21
The ETFAD recommends that for children, especially below
2 years of age, increased attention should be paid to the safety,
tolerability and hypoallergenic properties of all components of
topicals for the treatment and skincare of AD. Systemic treat-
ment should be initiated by experienced specialists only.
Specific considerations for adolescents
Adolescents are neither children nor adults, and to optimize the
management of their AD, some specific elements should be con-
sidered. Adolescent patients develop more autonomy and must
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learn to take care of their chronic disease in an independent way.
Adolescent becoming the actors of their own skincare must be
addressed directly and is possible without their parent’s pres-
ence. Specific aspects have to be discussed such as sleep habits,
daily skin treatment routine, management of comorbidities and
aspects of health-related quality of life such as peer relationships,
intimacy, sexuality and body image.274
Evaluation of daily skincare is essential. It seems that particu-
larly adolescents either do not bath or shower much or do so
with an excessive duration, which can aggravate AD and
increases the risk of skin infection.36 Adherence to a daily treat-
ment routine is very difficult in this age group. The risk of striae
from TCS absorption during puberty is high, and wet-wrapping
therapy with TCS should be used as a short-term therapy and
with caution only.275 Therefore, adolescents need clear advice on
how to use their TCS in combination with emollients276 and
specific age-related therapeutic patient educational programmes
should be discussed as effective long-term management strate-
gies of the disease.77
Teenagers with AD are more prone to specific types of allergic
contact dermatitis.277 The most frequent allergen is nickel. It
could be present not only in belt buckles, button flies and jew-
elleries, but also in cell phone covers and electronic devices.278
Adolescents with AD are more likely to experience psycholog-
ical challenges compared with their healthy peers. Children of all
age groups with AD had a significant increased risk of total men-
tal disorders compared with those without AD.279 Particularly in
late adolescence, AD is associated with suicidal ideation and
mental health problems.280 Adolescents with AD have a higher
risk of the developing a depressive or anxiety disorder later in
life.281 The relationship between suffering from AD and mental
disorders may be reciprocal.282
Most adolescents with AD have experienced social exclusion
or were bullied during childhood due to their skin disease, which
negatively affects self-perception and self-esteem.283 Older chil-
dren or adolescents reportedly have fewer friends, participate in
less social events or sports teams.284 The way an adolescent feels
about his body image is closely linked to self-esteem and difficul-
ties related to body image are common in adolescence. There-
fore, AD can also have a heavy impact on the capacity for
intimacy and sexual life, as it implicates appearance and personal
relationship. As quality of life correlates with the severity of AD
and psychological or social impairment, a holistic approach
could include psychological assessment, psychotherapy, beha-
vioural therapy and coping strategies.285,286
AD can have an impact on school performance and on future
professional life. Developing AD later during childhood or ado-
lescence could lead to a higher risk of having persistent AD in
adulthood, which can have an impact on the productivity at
work.287 However, having AD during adolescence does not seem
to negatively impact academic performance.288 Therefore, career
choices should be discussed with adolescent patients.
The ETFAD acknowledges the special requirements of adoles-
cent AD patients and recommends discussing them actively.
Occupational aspects
AD patients are running a significant risk of developing occupa-
tional contact dermatitis. Atopy amplifies the effects of irritant
and allergen exposure in hairdressers, cleaners, metalworkers,
mechanics and nurses, where hand eczema is a very common
disease.76 The skin of patients with AD is more reactive to skin
irritants, which in turn increases their risk of developing occupa-
tional irritant and allergic contact dermatitis on the hands.289
Accordingly, patients with AD have three- to fourfold increased
risk of occupational hand eczema.290
Occupations in which exposure to skin irritants such as water,
detergent, machine oil and gloves is common can therefore be
challenging for individuals with a history of AD. Physicians
should inform their patients with AD about these risks and pro-
vide careful guidance about prophylactic skin protection. The
risk of occupational hand eczema is generally higher for hair-
dressers, mechanics, bakers, chefs, nurses and painters. Adoles-
cents with AD should consider this when choosing their
profession.
The ETFAD recommends that preventive strategies should be
developed and optimized to reduce the incidence of occupa-
tional dermatitis in AD patients. Dermatologists should advise
their AD patients early on occupational aspects of their disease
and suitable career choices.
Psychosomatic aspects and therapeutic patient
education
Psychosomatic aspects of AD
Psychosomatic treatment could complement topical and sys-
temic therapy and should be divided into unimodal and multi-
modal psychological itch treatments.291 Depending on the
factors involved, a unimodal (e.g. progressive muscular relax-
ation or autogenic training) 292 or multimodal psychological
approach is recommended.291
The vicious itch-scratch cycle has to be considered when a
patient is treated for pruritus. The psychosomatic approach rec-
ognizes the itch patient with regard to coping behaviour and
possible stress attempts as cause or provocation factor in chronic
itch. Parents’ behaviour and skincare management may influ-
ence the severity of the disease.293 In addition to causal and
symptomatic therapy, behavioural therapy to avoid scratching
should be considered, e.g. conscious suppression of the reflex by
intense concentration, distraction or alternative scratching tech-
niques such as habit reversal.294 This is very important in
patients with AD and especially in those who might show an
unconscious automatic scratching behaviour.
Adjuvant psychosocial programmes focused on itch are most
effective in AD, and many randomized controlled trials have
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been published in the recent years.295–306 Such programmes
include strategies for breaking the vicious circle of itching and
scratching, relaxation and stress management techniques as well
as strategies for dealing with relapses. More than 10 randomized
controlled studies 296,307,308 and a Cochrane review about psy-
chological interventions showed slightly beneficial effects.309
Overall, counselling of AD patients is cost-effective.307,310
A similar educational programme was developed for patients
with chronic pruritus.311,312 It is currently established for in-pa-
tient hospital treatment of patients with pruritic dermatoses
using behavioural therapy in the context of an integrated psy-
chosomatic treatment.300,313 Habit-reversal techniques are espe-
cially effective as an additional management for itch in AD
patients.314 Relaxation techniques are easy to practice and are
demonstrated in specific age-related therapeutic patient educa-
tional programmes.22,77 In patients with coexisting depression,
psychotherapy in combination with psychotropic medication
can be helpful even to treat pruritus of different aetiology.315
Most publications on psychotherapeutic and psychopharmaco-
logic interventions, however, refer to small groups or single case
reports.316,317 Internet-delivered (eHealth) self-management was
investigated in recent years mostly with cognitive behavioural
interventions.306,318 Results demonstrate similar effects such as
face-to-face psychotherapy.319 Studies involving dermatologic
patients are promising.320
The ETFAD recommends multimodal education programmes
to increase coping behaviour in patients suffering from AD.
Relaxation techniques and habit-reversal techniques for AD
patients are also useful as a complementary treatment for
managing the disease.
Therapeutic patient education (eczema school)
Poor adherence to prescribed treatment is frequent and leads
to therapeutic failure.21 There is a significant and urgent need
for physicians to ensure that patients with AD are educated
and confident in using medication as prescribed to gain dis-
ease control. This education is designed to train patients or
parents of children suffering from AD in the skills of self-
management or adapting treatment to their particular chronic
disease and in coping processes and skills. Educational inter-
vention will help for the management of difficult-to-treat ato-
pic patients. Standardized interdisciplinary programmes
involving dermatologists, paediatricians, psychologists, psycho-
somatic counsellors and dietary counselling have been
demonstrated to improve subjective and objective symptoms,
optimize medication use in patients and result in a significant
gain in quality of life.22,77 Support materials for healthcare
professionals and for parents can be found on >www.fon
dation-dermatite-atopique.org<.
The ETFAD recommends participation in a therapeutic edu-
cation programme for AD to all patients with moderate and sev-
ere AD.
Optimizing patient adherence
Poor treatment adherence is one of the most common causes of
treatment failure. Hence, the ability to distinguish reliably
between non-adherence and non-response, and mastering the
active use of adherence-improving strategies are most important
for treating AD patients successfully.21 Factors influencing treat-
ment adherence include patient characteristics and beliefs, treat-
ment efficacy and duration, administration routes and disease
chronicity. Moreover, the quality of the physician–patient rela-
tionship including physician-time available for the patient as well
as ‘shared decision-making’ plays an important role.21 Strategies
to increase treatment adherence range from handing out written
action plans, minimizing treatment costs, thoughtfully scheduled
follow-up visits and reminder programmes to simplifying pre-
scriptions or educational interventions.21,273 A recent systematic
review summarizes the evidence and recommendations.21
Outlook and future perspectives
The simultaneous emergence of many new topical and systemic
drugs for the treatment of AD in clinical trials, and the perspec-
tive for some licensed systemic drugs even for childhood AD in
the near future have considerably changed the field of AD man-
agement. A combination of limited resources and increased digi-
talization will emphasize the quality of care as an important
issue also for the management of AD.321 The impact of the
COVID-19 pandemic on the availability of health care resources
for AD patients cannot be predicted, even if an interaction with
systemic medication seems low.322 A carefully selected topical
emollient therapy, allergen avoidance based on a thoroughly
taken history and allergy testing, and a wise selection of topical
anti-inflammatory therapy will still be needed in the future.
Therapeutic patient education for children, their caregivers and
adult patients suffering from AD supports and assures medical
treatment, as it is safe and cost-effective. Moreover, digitaliza-
tion of many aspects of patient care and artificial intelligence will
for sure enter the field of AD management. Many new aspects of
evidence-based care for AD patients will further change our daily
practice in the next 5 years. New patient leaflets replacing the
current ETFAD patient information sheet available at < https://
www.eadv.org/patient-corner/leaflets>, and additional online
information will witness these changes in due time.
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